Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Jérôme Avouac, MD,PhD

Université de Paris Cité
Paris, France

MD, PhD, Professor of Rheumatology at Cochin Hospital, Paris, France

Presentation(s):

  • 0053: The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0488: Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0489: Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1333: Assessment of Lipid Abnormalities After Initiation of a JAK Inhibitor in Rheumatoid Arthritis in Clinical Practice

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1334: Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1312: Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Fresenius kabi: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nordic: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)